Matrixyl (Palmitoyl Pentapeptide-4): Skincare Profile

Walk into any major skincare retailer today, and you'll find Matrixyl listed on dozens of anti-aging serums and creams. Since its launch in 2000 by French biotech firm Sederma, this synthetic peptide has become one of the most commercially successful cosmetic ingredients in the world. Its appeal is straightforward: clinical data suggests it can reduce wrinkle depth and improve collagen production with better tolerability than retinol, the longstanding gold standard for anti-aging skincare.

But what exactly is Matrixyl, and how does a five-amino-acid sequence derived from collagen send signals that tell skin cells to produce more extracellular matrix? The science behind this peptide bridges molecular biology, dermatology, and materials science. Understanding it requires digging into matrikine signaling, fibroblast receptor pathways, and the mechanics of how aging skin loses its structural integrity.

This profile examines the research — both industry-sponsored and independent — that supports Matrixyl's widespread use. We'll cover its mechanism of action, clinical trial data, practical application in skincare routines, safety considerations, and how it compares to other anti-aging actives.

Quick Facts
What Is Matrixyl?
How Matrixyl Works: Mechanisms of Action
Clinical Research and Evidence
How to Use Matrixyl in Skincare
Safety, Side Effects, and Tolerability
Frequently Asked Questions
Bottom Line

Quick Facts

Attribute	Details
Full Chemical Name	Palmitoyl Pentapeptide-4
INCI Name	Palmitoyl Pentapeptide-4
Other Names	Pal-KTTKS, Matrixyl, Palmitoyl-KTTKS
Peptide Type	Matrikine signaling peptide
Amino Acid Sequence	KTTKS (Lys-Thr-Thr-Lys-Ser) with palmitoyl group
Molecular Weight	802.05 Da (563.64 Da for base KTTKS sequence)
Developer	Sederma (now part of Croda)
Year Launched	2000
Application Route	Topical (cosmetic skincare)
Typical Concentration	2-8% (often 3% in formulations)
FDA Status	Cosmetic ingredient (not a drug)
CAS Number	214047-00-4

What Is Matrixyl?

Chemical Structure and Development

Matrixyl — officially known as palmitoyl pentapeptide-4 or pal-KTTKS — is a synthetic lipopeptide consisting of five amino acids (lysine-threonine-threonine-lysine-serine, or KTTKS) attached to a 16-carbon fatty acid chain called palmitic acid. The peptide sequence itself is not random. It comes directly from the C-terminal fragment of type I procollagen, the precursor molecule that cells produce before it matures into collagen.

In the early 1990s, researchers including Kazuhiro Katayama identified the KTTKS sequence as the minimal active segment capable of stimulating extracellular matrix (ECM) production in fibroblasts. Sederma, founded in 1964 as a French biotechnology company specializing in cosmetic actives, saw the therapeutic potential of this discovery. Under the leadership of key researcher Karl Lintner, Sederma modified the peptide by adding a palmitoyl group to the N-terminus.

This modification served two purposes: it increased the molecule's lipophilicity (affinity for fats), allowing it to penetrate the lipid-rich stratum corneum of skin more effectively, and it improved the peptide's stability in topical formulations. Sederma filed patents for these palmitoylated peptides in 1999 and launched Matrixyl commercially in 2000.

What Are Matrikines?

To understand how Matrixyl functions, you need to understand matrikines. These are bioactive peptide fragments generated when ECM proteins break down through proteolysis — the enzymatic cleavage of proteins. When collagen, elastin, or other structural proteins in the dermis degrade, they don't just disappear. The fragments left behind can act as signaling molecules.

Matrikines bind to specific receptors on the surface of dermal cells, particularly fibroblasts, and trigger cellular responses. These responses can include increased production of new ECM components, migration of cells to wound sites, and modulation of inflammatory pathways. In essence, matrikines function as messengers, informing cells about the state of the surrounding matrix and prompting repair mechanisms.

KTTKS is a naturally occurring matrikine. When type I collagen breaks down in aging or damaged skin, fragments containing the KTTKS sequence signal fibroblasts to ramp up collagen synthesis. Matrixyl mimics this natural process. By applying a synthetic version of this fragment topically, the goal is to "trick" fibroblasts into behaving as if matrix degradation is occurring, thereby stimulating repair and regeneration.

Relationship to Collagen Synthesis

Type I collagen is the most abundant structural protein in human skin, accounting for roughly 70-80% of the dermis's dry weight. It provides tensile strength and resilience. As we age, collagen production declines — by approximately 1% per year after age 30 — while collagen degradation increases due to matrix metalloproteinases (MMPs) and other enzymes activated by UV exposure, inflammation, and oxidative stress.

The pentapeptide sequence KTTKS is derived from the C-terminal propeptide of procollagen I, the immature precursor that fibroblasts secrete before it undergoes enzymatic processing into mature collagen fibrils. The KTTKS fragment acts as a feedback signal, indicating to fibroblasts that collagen turnover is happening and more synthesis is needed. By providing this signal exogenously through Matrixyl, the hypothesis is that you can boost collagen production even in aging skin where natural turnover has slowed.

How Matrixyl Works: Mechanisms of Action

Fibroblast Activation and ECM Signaling

The primary mechanism of Matrixyl centers on its interaction with dermal fibroblasts, the cells responsible for producing and maintaining the ECM. When Matrixyl penetrates the skin and reaches the dermis, it binds to specific receptors on fibroblast cell surfaces — likely integrins and growth factor receptors, though the exact binding partners are still debated in the literature.

This binding activates intracellular signaling cascades, including pathways involving transforming growth factor-beta (TGF-β), which is a key regulator of collagen gene expression. In vitro studies have shown that pal-KTTKS significantly increases procollagen secretion and upregulates type I collagen mRNA expression in cultured human dermal fibroblasts.

Beyond collagen, Matrixyl stimulates production of other ECM components:

Type III and IV collagen: Type III collagen provides structural support alongside type I, while type IV is a major component of the basement membrane at the dermal-epidermal junction.
Fibronectin: A glycoprotein that facilitates cell adhesion, migration, and wound healing.
Glycosaminoglycans (GAGs): Including hyaluronic acid, which retains moisture and provides volume to the dermis.

In vitro testing on human dermal fibroblasts demonstrated collagen upregulation of up to 90.9% at an 8 ppm concentration of pal-KTTKS, alongside elevated GAG production. Importantly, this stimulation occurred without affecting overall protein synthesis, suggesting a specific rather than generalized metabolic effect.

The Matrikine Concept in Skin Aging

The matrikine concept has profound implications for understanding skin aging and repair. Under normal conditions, the ECM is in dynamic equilibrium: synthesis balances degradation. In young, healthy skin, this turnover maintains structural integrity. As skin ages or sustains damage (particularly from UV radiation), this balance shifts toward net degradation.

Accumulated collagen fragments and damaged ECM proteins create a feedback loop. The degraded matrix physically impedes fibroblast function and alters the mechanical signals that cells receive from their environment. Fibroblasts in aged skin become less responsive to growth factors and produce less collagen even when stimulated.

Matrikines theoretically interrupt this cycle. By providing exogenous matrikine signals, you bypass some of the impaired signaling pathways in aged skin. The peptide doesn't depend on the cell detecting endogenous matrix breakdown — it delivers the "repair" message directly.

That said, this mechanism has limitations. Matrixyl's molecular weight of 802.05 Da exceeds the often-cited 500 Da threshold for easy penetration through the stratum corneum. While the palmitoyl modification improves lipophilicity and enhances penetration compared to the bare KTTKS peptide, whether sufficient quantities reach viable fibroblasts in the dermis remains a point of debate. Some researchers argue that most of the applied peptide remains in the upper epidermis or is degraded by proteases before reaching target cells.

Comparison to Retinoids

Retinoids (vitamin A derivatives like retinol and tretinoin) have long been considered the gold standard for anti-aging skincare. They work through a different mechanism: binding to retinoic acid receptors in the nucleus of skin cells, directly regulating gene transcription. This leads to increased collagen production, accelerated cell turnover, and reduced MMP expression.

Clinical comparisons between Matrixyl and retinoids show nuanced results. One French study compared 3 ppm pal-KTTKS with 700 ppm (0.07%) retinol on photoaged skin over four months. Both treatments increased skin thickness by approximately 9%, but data suggested that pal-KTTKS thickened skin about 1.5 times faster in the first two months. Critically, Matrixyl did not cause the irritation, redness, and flaking frequently associated with retinoid use.

This tolerability difference makes Matrixyl appealing for people with sensitive skin, rosacea, or those who cannot tolerate retinoids. However, retinol is generally considered more powerful for comprehensive anti-aging effects, including treating acne, fading hyperpigmentation, and improving skin texture. Matrixyl's primary strength is collagen stimulation with minimal irritation.

Some dermatologists recommend using both ingredients in combination, applied at different times (Matrixyl in the morning, retinol at night, for example) to leverage complementary mechanisms.

Clinical Research and Evidence

Sederma-Sponsored Studies

Much of the early evidence supporting Matrixyl comes from studies sponsored or conducted by Sederma. While industry-sponsored research should be interpreted with appropriate scrutiny, these studies provided the foundational data that drove the peptide's commercialization.

Lintner Study: In a double-blind trial by Lintner, participants applied 0.005% palmitoyl pentapeptide-4 cream around one eye twice daily for 28 days. The treated area showed quantitative reductions of:

Wrinkle depth: 18%
Wrinkle thickness: 37%
Skin firmness improvement: 21%

These measurements were obtained using profilometry and imaging analysis, providing objective rather than subjective assessments.

Matrixyl 3000 Clinical Study: A randomized, blind clinical study with 28 volunteers applied Matrixyl 3000 (a combination peptide containing both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, distinct from Matrixyl/palmitoyl pentapeptide-4) cream twice daily. After two months, results showed:

45% reduction in wrinkle depth
Decreased wrinkle volume and density
Reduced skin roughness and complexity
Increase in skin tone

Note that Matrixyl 3000 is a related but different formulation from the original Matrixyl (pal-KTTKS). Marketing materials sometimes conflate the two.

Independent Clinical Trials

Independent research provides a more balanced perspective.

Robinson et al. (2005): This 12-week, double-blind, placebo-controlled, split-face study enrolled 93 Caucasian women aged 35-55. Participants applied a moisturizer containing 3 ppm palmitoyl pentapeptide to one side of the face and placebo to the other, twice daily.

Results showed statistically significant improvements on the peptide-treated side:

Reduced wrinkles and fine lines (both by quantitative technical analysis and expert grader assessment)
Improved skin barrier function
Increased elastin fiber density and thickness in biopsy samples
Better regulation of collagen IV at the dermal-epidermal junction

The study also documented improved skin roughness, wrinkle volume, and wrinkle depth compared to vehicle control. Importantly, the formulation was well tolerated with no significant adverse events.

Asian Population Study: A more recent double-blind randomized trial in Indonesia enrolled 21 women aged 26-55, comparing palmitoyl pentapeptide-4 cream, acetylhexapeptide-3 (Argireline) cream, and placebo over eight weeks for treatment of crow's feet. Palmitoyl pentapeptide-4 demonstrated better results than acetylhexapeptide-3 based on clinical photos, wrinkle depth measurements, and participant questionnaires.

Higher Concentration Studies: Some research has examined higher concentrations. A study using 7% palmitoyl pentapeptide-4 serum in a split-face design for eight weeks measured periorbital wrinkle depth, skin viscoelasticity, and trans-epidermal water loss, though full results are not widely published in peer-reviewed literature.

Limitations and Criticisms

Despite positive findings, several caveats exist:

Limited Peer-Reviewed Literature: There isn't extensive independent, peer-reviewed research conclusively proving Matrixyl's efficacy for facial wrinkles. Much available data comes from industry sources or journals with less rigorous review processes.
Penetration Doubts: The 802 Da molecular weight raises questions about dermal penetration. While the palmitoyl group helps, it's unclear if enough active peptide reaches fibroblasts to produce clinically significant effects in real-world use.
Concentration Variability: Commercial products contain widely variable concentrations, often proprietary blends where the actual peptide content is unclear. Some serums advertise "10% Matrixyl" but this often refers to a premixed solution where the actual pal-KTTKS content is much lower (potentially under 0.1%).
Slow Results: Collagen turnover takes time. Visible improvements typically require 8-12 weeks of consistent use, which limits compliance and makes it harder to attribute results specifically to the peptide versus other skincare practices or ingredients.
Formulation Dependence: Performance depends heavily on formulation. Peptide stability, vehicle choice, pH, and presence of complementary ingredients all influence whether the active ingredient remains effective by the time it's applied.

How to Use Matrixyl in Skincare

Product Selection and Concentration

When choosing a Matrixyl product, look for concentrations between 2-8%, with 3% being a common clinical benchmark. However, because manufacturers often list "Matrixyl solution" rather than pure peptide content, verifying actual concentration is difficult. Reputable brands should specify the peptide form (palmitoyl pentapeptide-4) explicitly.

Serums are preferable to creams for several reasons:

Higher concentration of actives
Better penetration due to lighter vehicle
Easier to layer with other products

Look for products that:

List palmitoyl pentapeptide-4 (or pal-KTTKS) in the first third of the ingredient list
Have a pH close to skin's natural pH (4.5-5.5) to optimize peptide stability
Include complementary ingredients like hyaluronic acid for hydration or antioxidants for stability
Are packaged in opaque, airless pumps to prevent degradation

Application Guidelines

Timing: Apply Matrixyl serums after cleansing and toning but before heavier moisturizers and oils. Peptides work best on damp skin, as water can aid penetration.

Frequency: Twice daily (morning and evening) is standard in clinical studies. Consistency matters more than generous application — a pea-sized amount for the entire face is sufficient.

Duration: Expect to wait 8-12 weeks to see visible results. Collagen synthesis is a slow process, and existing damaged collagen doesn't disappear overnight.

Layering: Matrixyl is generally compatible with most skincare ingredients:

With vitamin C: Safe to combine. Apply vitamin C first (lower pH), wait a few minutes, then apply Matrixyl.
With retinol: Can be used together but consider alternating times (Matrixyl morning, retinol evening) or on alternate nights if irritation occurs.
With niacinamide, hyaluronic acid, peptides: No known interactions.
With AHAs/BHAs: Use acids first, wait 15-20 minutes, then apply peptides. Low pH from acids may temporarily compromise peptide stability if applied simultaneously.

Combination with Other Anti-Aging Actives

Matrixyl works well as part of a comprehensive anti-aging routine rather than as a standalone treatment. Consider combining with:

Retinoids: For comprehensive collagen stimulation, cell turnover, and pigmentation improvement. Use Matrixyl as a gentler complementary peptide or as a retinoid alternative during summer months when skin is more sun-sensitive.
Copper peptides like GHK-Cu: Target different aspects of skin remodeling (wound healing, inflammation modulation). Can be layered with Matrixyl.
Antioxidants (vitamin C, vitamin E, ferulic acid): Protect existing collagen from oxidative damage while Matrixyl stimulates new synthesis.
Sunscreen: Non-negotiable. UV exposure is the primary driver of collagen degradation. Without daily broad-spectrum SPF 30+, any collagen-boosting efforts are futile.

Beyond Facial Skincare

While Matrixyl is primarily marketed for facial anti-aging, research has explored other applications:

Wound Healing: Studies show that Matrixyl can accelerate wound healing by promoting collagen deposition and reducing inflammatory markers. Both patch and cream formulations were effective, with patches providing sustained delivery.
Body Skin: Can be applied to neck, décolletage, and hands, areas that show visible aging but are often neglected.
Eye Area: Many formulations specifically target periorbital wrinkles (crow's feet), where skin is thin and vulnerable to repetitive muscle movement.

Safety, Side Effects, and Tolerability

Safety Profile

Matrixyl has an excellent safety record. The Cosmetic Ingredient Review (CIR) Expert Panel assessed palmitoyl pentapeptide-4 and related peptides, concluding they are safe as used in cosmetics. The Environmental Working Group (EWG) gives palmitoyl pentapeptide-4 a score of 1 (very safe) on its 1-10 scale.

Concentrations up to 3% have been proven safe, non-irritating, and non-sensitizing in clinical trials, well tolerated across all skin types including oily and acne-prone skin.

Potential Side Effects

Adverse reactions are rare. When they occur, symptoms include:

Mild redness or irritation (typically from other formulation ingredients rather than the peptide itself)
Transient stinging, especially in heavier, occlusive vehicles
Dryness (often related to improper formulation pH or vehicle)
Breakouts (more likely due to comedogenic carrier oils or emollients in the product)

True allergic reactions to palmitoyl pentapeptide-4 are uncommon but possible, as with any cosmetic ingredient. If redness, swelling, or itching persists, discontinue use and consult a dermatologist.

Systemic Absorption and Drug Interactions

Systemic absorption through intact skin is minimal. As a large peptide (802 Da) with limited penetration beyond the dermis, Matrixyl is unlikely to enter circulation in significant amounts. This makes it safe for pregnant and breastfeeding women from a systemic exposure standpoint, though topical cosmetic use on the face is generally considered lower risk than unknown systemic effects.

There are no known drug interactions with palmitoyl pentapeptide-4. It does not interact with oral medications, and topical co-application with prescription treatments (tretinoin, hydroquinone, etc.) has not shown adverse interactions.

Skin Type Considerations

Sensitive skin: Matrixyl is one of the gentler anti-aging actives, making it appropriate for sensitive, reactive, or rosacea-prone skin that cannot tolerate retinoids.
Oily/acne-prone: No evidence suggests Matrixyl causes or worsens acne. Ensure the vehicle is non-comedogenic (avoid heavy oils and silicones if breakout-prone).
Dry/mature: Ideal candidate for peptide therapy. Pair with rich moisturizers and occlusives to maximize barrier function.
All skin types: Generally safe across Fitzpatrick types I-VI, with no known increased risk of hyperpigmentation or other concerns for darker skin tones.

Long-Term Use

No evidence suggests that long-term continuous use of Matrixyl causes tachyphylaxis (reduced response over time) or other negative effects. Because it works through signaling rather than direct enzymatic inhibition or receptor blocking, sustained daily use over months or years is considered safe.

However, peptide stability degrades over time in opened containers. For maximum efficacy, use products within 3-6 months of opening and store in cool, dark locations.

Frequently Asked Questions

Is Matrixyl better than retinol?

Not definitively. Retinol generally provides more comprehensive anti-aging benefits, including improved cell turnover, fading of hyperpigmentation, and acne treatment alongside collagen stimulation. However, Matrixyl is significantly gentler and better tolerated, making it a viable alternative for people with sensitive skin, rosacea, or those who experience irritation from retinoids. Clinical data suggests Matrixyl may produce similar wrinkle reduction at much lower concentrations (0.0003% peptide vs 0.07% retinol), with fewer side effects. The best choice depends on your skin's tolerance and your specific concerns.

How long does it take to see results from Matrixyl?

Clinical studies typically measure outcomes at 8-12 weeks of twice-daily use. Collagen synthesis is a slow biological process — new collagen must be produced, organized into fibrils, and integrated into the existing ECM before structural improvements become visible. Some users report subtle improvements in skin texture within 4-6 weeks, but meaningful wrinkle reduction generally requires at least two months of consistent application. Patience and consistency are key.

Can I use Matrixyl with vitamin C?

Yes. There's no known interaction between Matrixyl and vitamin C (ascorbic acid or its derivatives). For optimal stability, apply vitamin C first (it typically has a lower pH around 3-3.5), wait a few minutes for it to absorb, then apply Matrixyl serum. Some formulations combine both ingredients, though this requires careful pH balancing to maintain the stability of both actives.

What's the difference between Matrixyl, Matrixyl 3000, and Matrixyl Synthe'6?

These are different peptide formulations developed by Sederma:

Matrixyl (palmitoyl pentapeptide-4): The original, consisting of the single pal-KTTKS peptide. Stimulates collagen I, III, IV, fibronectin, and GAGs.
Matrixyl 3000: A combination of two peptides — palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. Designed to stimulate collagen synthesis while also reducing inflammation. Clinical data shows comparable or superior wrinkle reduction to original Matrixyl.
Matrixyl Synthe'6: A hexapeptide (palmitoyl tripeptide-38) targeting six key components of the dermal matrix: collagen I, III, IV, fibronectin, hyaluronic acid, and laminin-5. Marketed as providing a "filling" effect for wrinkles.

Each has distinct clinical profiles, and some products contain combinations of these peptides.

Does Matrixyl actually penetrate the skin?

This is debated. Matrixyl's molecular weight of 802 Da exceeds the often-cited 500 Da threshold for easy penetration through the stratum corneum. The palmitoyl group increases lipophilicity, which helps it traverse lipid bilayers, but whether sufficient quantities reach viable dermal fibroblasts remains uncertain. Clinical studies demonstrating efficacy suggest some penetration occurs, but formulation quality, skin hydration status, and other factors likely significantly impact bioavailability. Using Matrixyl on damp skin after active penetration enhancers (like glycolic acid) may improve delivery.

Can Matrixyl cause skin purging or breakouts?

Unlike retinoids and AHAs, Matrixyl does not increase cell turnover, so it should not cause purging (the temporary breakout phase when dead skin cells trapped in pores are shed more rapidly). If breakouts occur, they're more likely due to comedogenic ingredients in the product vehicle (certain oils, emulsifiers, or silicones) rather than the peptide itself. If you have acne-prone skin, look for non-comedogenic, lightweight formulations.

Is Matrixyl safe during pregnancy and breastfeeding?

From a systemic absorption standpoint, Matrixyl is likely safe given its large molecular size and minimal penetration beyond the dermis. However, comprehensive safety data for use during pregnancy and lactation are limited. Topical cosmetics applied to the face are generally lower risk than systemic medications. If concerned, consult with an OB-GYN or dermatologist. Many pregnant women choose peptides as safer alternatives to retinoids, which are contraindicated in pregnancy.

Do I need to use sunscreen with Matrixyl?

Absolutely. While Matrixyl itself does not increase photosensitivity like retinoids or AHAs, UV exposure is the primary driver of collagen degradation and photoaging. Using Matrixyl to stimulate collagen synthesis while allowing UV damage to destroy existing collagen is counterproductive. Daily broad-spectrum SPF 30+ is essential for any anti-aging regimen.

Bottom Line

Matrixyl (palmitoyl pentapeptide-4) represents a scientifically rational approach to anti-aging skincare. By mimicking a naturally occurring collagen-derived matrikine, it signals dermal fibroblasts to boost production of collagen, fibronectin, and other extracellular matrix components. Clinical data — both industry-sponsored and independent — shows statistically significant improvements in wrinkle depth, skin thickness, and texture with good tolerability and minimal side effects.

However, the evidence has limitations. Penetration questions persist given the peptide's molecular weight. The available peer-reviewed literature, while supportive, is not extensive. Most dramatic marketing claims extrapolate from controlled studies under ideal conditions that may not reflect real-world product performance.

Matrixyl shines as a gentler alternative to retinoids for people with sensitive skin or those seeking collagen stimulation without irritation. It works well as part of a comprehensive anti-aging routine that includes sunscreen, antioxidants, and other actives targeting different aspects of skin aging. Realistic expectations are key: visible results require months of consistent use, and Matrixyl will not replicate the comprehensive benefits of prescription retinoids or in-office procedures.

For individuals looking to incorporate evidence-based peptides into their skincare, Matrixyl remains one of the most studied and accessible options. Just remember that no single ingredient is a panacea. Skin aging is multifactorial, and addressing it effectively requires a multifaceted approach.

Disclaimer: This article is for informational and educational purposes only. It is not medical advice. Matrixyl is a cosmetic ingredient, not a drug, and is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a dermatologist or healthcare provider before starting any new skincare regimen, especially if you have sensitive skin, skin conditions, or are pregnant or breastfeeding. This content has not been evaluated by the FDA.

References

Robinson LR, et al. (2005). Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science.
Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literature. Clinical, Cosmetic and Investigational Dermatology, 2016.
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. Dermatology Reports, 2023.
Palmitoyl pentapeptide-4. Wikipedia.
The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Biomolecules, 2019.
Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process. Tissue Engineering and Regenerative Medicine, 2018.
Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing. ACS Omega, 2022.
Lintner K. Matrixyl clinical studies. Sederma Research.
A new matrikine-derived peptide up-regulates longevity genes for improving extracellular matrix architecture. International Journal of Cosmetic Science, 2020.
Matrikines as mediators of tissue remodelling. Advanced Drug Delivery Reviews, 2022.
Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures. Journal of Drugs in Dermatology, 2016.
Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4. Cosmetic Ingredient Review, 2023.
Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics, 2015.
Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. International Journal of Molecular Sciences, 2025.
Matrixyl in Skin Care Serums and Creams: Does it Work?. Skin Type Solutions.
Is Matrixyl A Gentler Alternative To Retinol?. Beautiful With Brains.
Matrixyl 3000 vs Retinol: Which One Fights Aging Better?. Skin Deva.
Can You Use Matrixyl With Retinol?. Rixincosmetics.
Matrixyl Guide: Benefits, How It Fits in Your Routine. Superpower.
Matrixyl Peptide 101: Benefits, Uses & Anti-Aging Skincare Guide. Truly Beauty.

Table of Contents